JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 2, 2005; DOI: 10.1124/jpet.105.085050


0022-3565/05/3143-1218-1225$20.00
JPET 314:1218-1225, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.085050v1
314/3/1218    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arp, J.
Right arrow Articles by Dekaban, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arp, J.
Right arrow Articles by Dekaban, G. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

TOXICOLOGY

Hypersensitivity of HIV-1-Infected Cells to Reactive Sulfonamide Metabolites Correlated to Expression of the HIV-1 Viral Protein Tat

Jacqueline Arp, Michael J. Rieder, Brad Urquhart, David Freeman, M. Jane Tucker, Adriana Krizova, David Lehmann, and Gregory A. Dekaban

The BioTherapeutics Group, Robarts Research Institute London, Ontario, Canada (J.A., M.J.R., G.A.D.); Section of Paediatric Clinical Pharmacology, Departments of Paediatrics (M.J.T.), Physiology and Pharmacology (A.K., B.U.), and Medicine (D.F.), Children's Hospital of Western Ontario, University of Western Ontario, London, Ontario, Canada; and Departments of Medicine and Pharmacology, State University of New York, Health Sciences Center Syracuse, Syracuse, New York (D.L.)

Impairment of human immunodeficiency virus (HIV)-infected cells to deal with reactive drug metabolites may be a mechanism for the increased rate of adverse drug reactions seen in AIDS. HIV Tat protein expression may be associated with increased oxidative stress within HIV-infected cells. To determine the relationship between expression of HIV Tat and sensitivity to reactive drug metabolites, we studied toxicity of sulfamethoxazole (SMX) and its reactive hydroxylamine intermediate (SMX-HA) in lymphocytes transfected with the HIV tat gene. Over a concentration range from 0 to 400 µM SMX-HA, there was a significant concentration-dependent increase in cell death in transfected cell lines expressing Tat compared with controls. Jurkat T cells transfected with a dose-dependent inducible tat gene showed increased toxicity in response to SMX-HA as more Tat expression was induced. Enhanced sensitivity to SMX-HA was accompanied by significantly lower concentrations of total intracellular glutathione compared with controls (P < 0.05). Sensitivity to reactive drug metabolites in HIV-infected cells seems to be mediated by the viral protein Tat.


Received February 16, 2005; accepted May 27, 2005.

Address correspondence to: Dr. M. Rieder, Department of Paediatrics, Children's Hospital of Western Ontario, 800 Commissioner's Rd. East, London, ON, Canada N6C 2V5. E-mail: mrieder{at}uwo.ca




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
D. Lin, M J. Tucker, and M. J Rieder
Increased Adverse Drug Reactions to Antimicrobials and Anticonvulsants in Patients with HIV Infection
Ann. Pharmacother., September 1, 2006; 40(9): 1594 - 1601.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.